(NASDAQ: ADIL) Adial Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.98%.
Adial Pharmaceuticals's earnings in 2026 is -$7,977,171.On average, 4 Wall Street analysts forecast ADIL's earnings for 2026 to be -$8,906,677, with the lowest ADIL earnings forecast at -$10,271,674, and the highest ADIL earnings forecast at -$7,331,912. On average, 3 Wall Street analysts forecast ADIL's earnings for 2027 to be -$3,772,411, with the lowest ADIL earnings forecast at -$3,624,473, and the highest ADIL earnings forecast at -$3,883,364.
In 2028, ADIL is forecast to generate -$2,432,404 in earnings, with the lowest earnings forecast at -$2,337,016 and the highest earnings forecast at -$2,503,945.